Abstract
The CB1 receptor is expressed in the central nervous system and numerous other tissues including heart, lung and uterus and has been recognized as an important therapeutic target for pain, appetite modulation, glaucoma, multiple sclerosis and other indications. An interesting feature of this GPCR is its ability to be activated by a number of structurally different classes of compounds, thus, raising the possibility of multiple activated forms of the receptor. Understanding of the structure-activity relationships of cannabinergic ligands has paved the road for the development of novel ligands exhibiting receptor subtype selectivity and efficacy. This review highlights the important CB1 cannabinergic ligands developed to date.
Keywords: cannabinoid receptors, cb agonists, cb antagonists, cb selectivity
Mini-Reviews in Medicinal Chemistry
Title: CB1 Cannabinoid Receptor Ligands
Volume: 5 Issue: 7
Author(s): Ganesh A. Thakur, Spyros P. Nikas and Alexandros Makriyannis
Affiliation:
Keywords: cannabinoid receptors, cb agonists, cb antagonists, cb selectivity
Abstract: The CB1 receptor is expressed in the central nervous system and numerous other tissues including heart, lung and uterus and has been recognized as an important therapeutic target for pain, appetite modulation, glaucoma, multiple sclerosis and other indications. An interesting feature of this GPCR is its ability to be activated by a number of structurally different classes of compounds, thus, raising the possibility of multiple activated forms of the receptor. Understanding of the structure-activity relationships of cannabinergic ligands has paved the road for the development of novel ligands exhibiting receptor subtype selectivity and efficacy. This review highlights the important CB1 cannabinergic ligands developed to date.
Export Options
About this article
Cite this article as:
Thakur A. Ganesh, Nikas P. Spyros and Makriyannis Alexandros, CB1 Cannabinoid Receptor Ligands, Mini-Reviews in Medicinal Chemistry 2005; 5 (7) . https://dx.doi.org/10.2174/1389557054368772
DOI https://dx.doi.org/10.2174/1389557054368772 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A PHACES Syndrome Unmasked by Propranolol Interruption in a Tetralogy of Fallot Patient: Case Report and Extensive Review on New Indications of Beta Blockers
Current Medicinal Chemistry Modulation of the Peripheral and Central Inflammatory Responses by a-Melanocyte Stimulating Hormone
Current Protein & Peptide Science Message from the Editor-in-Chief
CNS & Neurological Disorders - Drug Targets Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Neurotrophic Effects of the Peptide NAP: A Novel Neuroprotective Drug Candidate
Current Alzheimer Research Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Burkholderia mallei and Burkholderia pseudomallei: The Causative Micro-organisms of Glanders and Melioidosis
Recent Patents on Anti-Infective Drug Discovery Corticotropin Releasing Factor (CRF) Receptor Signaling in the Central Nervous System: New Molecular Targets
CNS & Neurological Disorders - Drug Targets Recent Advances in the Molecular Pathogenesis of Dystonia-Plus Syndromes and Heredodegenerative Dystonias
Current Neuropharmacology Meet Our Editorial Board Member:
Current Molecular Pharmacology Co-Morbidity of APD and Reading Disabilities
Current Pediatric Reviews Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Novel 5-HT7 Ligands as Antidepressants: Automated Synthesis of NSubstituted- N-[1-Methyl-3-(4-Methylpiperidin-1-yl)propyl]-Arylsulfonamides
Letters in Drug Design & Discovery Serotonin Transporter Gene Variants and Behavior: A Comprehensive Review
Current Drug Targets Challenges in Lung Cancer Approaches: from the Clinical Issues to the Novel Therapies
Recent Advances in DNA & Gene Sequences (Discontinued) Major Depressive Disorder in Neuroimaging: What is Beyond Fronto-limbic Model?
Current Psychiatry Research and Reviews HIV-1 Tat-Mediated Calcium Dysregulation and Neuronal Dysfunction in Vulnerable Brain Regions
Current Drug Targets The Protective Effect of Jatrorrhizine Against Oxidative Stress in Primary Rat Cortical Neurons
CNS & Neurological Disorders - Drug Targets Sepsis Pathophysiology and Anesthetic Consideration
Cardiovascular & Hematological Disorders-Drug Targets Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies
Current Neuropharmacology